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1. Introduction {#jia225429-sec-0005}
===============

A recent meta‐analysis showed increasing trend in HIV drug resistance (DR) to non‐nucleoside reverse transcriptase inhibitors (NNRTI) in people living with HIV (PLHIV) starting first‐line antiretroviral therapy (ART) in Latin America since 2007 [1](#jia225429-bib-0001){ref-type="ref"}. This emergence of NNRTI pretreatment drug resistance (PDR) threatens the effectiveness of first‐line NNRTI‐based ART, currently the preferred option in most countries of the region [2](#jia225429-bib-0002){ref-type="ref"}.

In Nicaragua, ART scale‐up has been ongoing since 2003 [3](#jia225429-bib-0003){ref-type="ref"}. In 2018, among 9400 estimated PLHIV, 5000 (53%) were on ART and 3,700 (40%) had achieved viral load (VL) suppression [4](#jia225429-bib-0004){ref-type="ref"}. ART abandonment rates as high as 30% have been previously reported [5](#jia225429-bib-0005){ref-type="ref"}. Low VL suppression rate represents an important risk for acquired drug resistance (ADR) and further PDR transmission [6](#jia225429-bib-0006){ref-type="ref"}. According to the national ART guidelines, the preferred first‐line regimen for adults in Nicaragua is NNRTI‐based (efavirenz (EFV)) and a protease inhibitor (PI)‐based second‐line regimen is used after confirmed viral failure (two consecutive unsuppressed VL measurements within a 2‐month interval with adherence support, after at least six months on ART) [3](#jia225429-bib-0003){ref-type="ref"}. VL and CD4 count are performed semi‐annually for ART monitoring, but HIVDR testing is not routinely available [3](#jia225429-bib-0003){ref-type="ref"}. A 2011 to 2015 sentinel survey among ART‐naive PLHIV enrolled at Nicaragua\'s largest HIV clinic, Roberto Calderon Hospital, found increasing rates of NNRTI PDR, with overall prevalence of 11.3% (95% confidence interval (CI): 7.9% to 15.6%) [7](#jia225429-bib-0007){ref-type="ref"}.

In response to rising levels of NNRTI PDR in low‐ and middle‐income countries (LMIC), the World Health Organization (WHO) developed a Global Action Plan with a 5‐year framework [8](#jia225429-bib-0008){ref-type="ref"} that strongly recommends the implementation of nationally representative HIVDR surveys based on a standardized methodology [9](#jia225429-bib-0009){ref-type="ref"}. Implementation of HIVDR surveillance strategies at the country level is critical to not only inform policy and advocate for updated ART guidelines, but also to better understand HIVDR locally [6](#jia225429-bib-0006){ref-type="ref"}, [10](#jia225429-bib-0010){ref-type="ref"}.

Given the worrying scenario of HIVDR in Nicaragua and following WHO recommendations, we performed a nationally representative survey to estimate PDR and ADR among PLHIV on ART for 12 ± 3 months (ADR12) and ≥48 months (ADR48).

2. Methods {#jia225429-sec-0006}
==========

2.1. Study design {#jia225429-sec-0007}
-----------------

We carried out a cross‐sectional survey with a two‐stage cluster sampling, following WHO‐recommended methods [11](#jia225429-bib-0011){ref-type="ref"}, [12](#jia225429-bib-0012){ref-type="ref"}. Nineteen out of a total of 45 ART clinics were selected, excluding smaller clinics (n = 26) that combined comprised \<10% of the national cohort of adults on ART. The sample size was calculated based on the probability proportional to proxy size sampling approach to obtain outcome estimates with a CI of ±5%. The following model assumptions were made for PDR survey sample size calculation: 10% prevalence of PDR, 20% genotyping failure, 25% of ART initiators with prior exposure to ARVs, and 100% expected proportion of individuals initiating ART with NNRTI‐based regimens; and for ADR surveys sample size calculation: 85% expected prevalence of VL suppression, 15% expected laboratory (VL and genotyping) failure rate, 95% expected proportion of persons still on first‐line ART, and 100% expected proportion of individuals on first‐line NNRTI‐based regimens. The total sample size per survey was calculated using the WHO standardized Microsoft Excel‐based calculator [13](#jia225429-bib-0013){ref-type="ref"}, and the number of participants per clinic were assigned proportionally to clinic size. Target sample sizes were 239 for PDR, 262 for ADR12 and 376 for ADR48.

2.2. Survey enrolment {#jia225429-sec-0008}
---------------------

ART initiators ≥18 years, defined as PLHIV initiating (self‐reporting no prior exposure to ARV and including persons with unknown exposure to ARVs) or reinitiating (after experiencing an ART interruption of at least three months) first‐line ART, were included in the PDR survey. PLHIV (≥18 years old) on ART for 12 (±3) months for ADR12 or ≥48 months for ADR48, were included. Participant enrolment took place during March--November 2016. All eligible PLHIV were approached and those who voluntarily consented to participate in the survey were included until the sample size at each clinic was reached or until the end of the enrolment period.

Demographic data were collected on paper‐based forms by trained Ministry of Health staff, using a survey identification code linked to VL, CD4 count and HIVDR testing results.

2.3. Specimen collection, handling, storage and laboratory procedures {#jia225429-sec-0009}
---------------------------------------------------------------------

Whole blood specimens were collected and shipped to the WHO‐designated regional reference laboratory in Mexico City for VL, CD4 count and HIVDR testing within a week from sample collection, following laboratory standard operational procedures.

HIVDR testing was performed on specimens with VL ≥1000 copies/mL according to the WHO/HIV ResNet Laboratory Operational Framework [14](#jia225429-bib-0014){ref-type="ref"}. Briefly, HIV protease and reverse transcriptase were amplified from plasma virus, using an in‐house‐validated protocol (HXB2: 2243 to 3304) and sequences were obtained on a 3730xl Genetic Analyser (ThermoFisher, Waltham, MA) [15](#jia225429-bib-0015){ref-type="ref"}. Integrase (IN) was amplified and sequenced separately, using an in‐house‐validated protocol (HXB2: 4013 to 5265) [16](#jia225429-bib-0016){ref-type="ref"}, [17](#jia225429-bib-0017){ref-type="ref"}.

Sequences were assembled using the web‐based automated sequence analysis tool ReCall (British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada) [18](#jia225429-bib-0018){ref-type="ref"}. Post‐testing quality assurance was carried out using the WHO HIVDR quality control tool (<http://pssm.cfenet.ubc.ca/who_qc/>). All sequence pairs with genetic distance \<0.5% within the same sequencing batch were repeated and confirmed.

2.4. Data analysis {#jia225429-sec-0010}
------------------

VL suppression was defined as \<1000 copies/mL. Any HIVDR was defined as the presence of a penalty score ≥15 using the Stanford HIVdb tool (v8.2) [19](#jia225429-bib-0019){ref-type="ref"} to one or more of the following ARVs: nevirapine (NVP), EFV, any nucleoside reverse transcriptase inhibitor (NRTI), boosted darunavir, boosted lopinavir (LPV/r) or boosted atazanavir. HIVDR to NNRTI referred to NVP, EFV or both. HIVDR to the preferred first‐line ART regimen referred to tenofovir (TDF) + emtricitabine (FTC) + EFV. HIVDR to the preferred second‐line ART regimen referred to zidovudine (AZT) + lamivudine (3TC) + LPV/r. HIV subtype was assigned using REGA HIV‐1 subtyping tool V3 [20](#jia225429-bib-0020){ref-type="ref"}.

Data analysis was performed following the HIVDR WHO Data Analysis guidelines using STATA 15.1 (StataCorp, College Station, TX, USA), and accounted for all‐sites survey design and sampling weights [11](#jia225429-bib-0011){ref-type="ref"}, [12](#jia225429-bib-0012){ref-type="ref"}. The outputs were weighted considering the clinic sampling weight, the estimated eligible population sizes per clinic, the number of eligible individuals enrolled and the number of sequences available.

Retention‐adjusted VL suppression was calculated using the country estimate of adults known to be on ART 12 months after ART initiation (72.0%) [21](#jia225429-bib-0021){ref-type="ref"} multiplied by the VL suppression estimates, and a Wald 95% CI was calculated using the associated variance.

2.5. Ethics statement {#jia225429-sec-0011}
---------------------

The institutional review boards of the Universidad del Valle de Guatemala and National Institute of Respiratory Diseases in Mexico revised and approved the study. All participants provided written informed consent prior to enrolment.

3. Results and discussion {#jia225429-sec-0012}
=========================

3.1. Clinical and demographic characteristics of participants {#jia225429-sec-0013}
-------------------------------------------------------------

A total of 638 participants were enrolled in the surveys: 171 (71.5% of the sampling goal) for PDR, 114 (43.5%) for ADR12 and 353 (93.8%) for ADR48. Among ART initiators, 71.9% (123/171) were male, 43.8% (74/171) had CD4 count \<200 cells/µL, and 86.0% (148/171) initiated ART with the preferred first‐line ART regimen (TDF + FTC+EFV). Among PLHIV on ART, 97.8% were on first‐line at 12 months of ART initiation, decreasing to 84.8% at ≥48 months on ART (Table [1](#jia225429-tbl-0001){ref-type="table"}).

###### 

Demographic and clinical characteristics of ART initiators and PLHIV on ART in Nicaragua, 2016[a](#jia225429-note-0004){ref-type="fn"}

                                                                 ART initiators (PDR; N = 171)   PLHIV on ART                                                          
  -------------------------------------------------------------- ------------------------------- -------------- -------------- ---- ------ -------------- ----- ------ --------------
  Sex                                                                                                                                                                  
  Male                                                           123                             71.9           64.3 to 78.5   76   66.6   56.0 to 75.7   219   57.0   49.5 to 64.2
  Female                                                         48                              28.1           21.5 to 35.7   38   33.5   24.3 to 44.0   134   43.0   35.8 to 50.5
  Age (years), median (IQR)                                                                      32             26 to 42            32     26 to 39             37.0   32 to 48
  ≤25                                                            41                              24.6           20.5 to 29.1   27   33.3   23.9 to 44.4   27    9.0    5.7 to 14.0
  \>25                                                           30                              75.4           70.9 to 79.5   87   66.7   55.6 to 76.1   326   91.0   86.0 to 94.3
  CD4 count (cells/µL), median (IQR)                                                             247            82 to 432           400    213 to 620           416    202 to 654
  \<200                                                          74                              43.8           33.9 to 54.2   25   17.2   13.2 to 22.1   87    23.7   20.1 to 27.7
  200 to 500                                                     66                              38.3           32.1 to 45.0   41   40.1   29.4 to 51.9   130   36.4   32.1 to 41.0
  \>500                                                          31                              17.9           9.9 to 30.2    48   42.7   31.8 to 54.3   136   39.9   35.3 to 44.6
  ART regimen                                                                                                                                                          
  First‐line[b](#jia225429-note-0005){ref-type="fn"}             70                              99.4           94.9 to 99.9   10   97.8   97.7 to 97.9   303   84.8   79.2 to 89.1
  Preferred first‐line[c](#jia225429-note-0006){ref-type="fn"}   48                              85.9           76.7 to 91.8   91   75.2   64.7 to 83.3   17    32.4   26.8 to 38.6
  Second‐line                                                    NA                                                            4    2.2    2.1 to 2.3     49    14.4   10.4 to 19.5
  Third‐line                                                     NA                                                            NA                         1     0.8    0.1 to 5.6
  No data                                                        1                               0.6            0.0 to 5.0     NA                         NA            

ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; FTC, emtricitabine; IQR, interquartile range; NA, not applicable; TDF, tenofovir.

Study design‐weighted proportions and 95% confidence interval

one ART initiator had missing data for initiated first‐line ART

preferred first‐line ART regimen: TDF + FTC + EFV.

John Wiley & Sons, Ltd

The most important limitation of the present study is that target sample size for the PDR and ADR12 surveys was not achieved due to logistic constrains, low national ART retention rate and short enrolment periods for some clinics. This is a critical limitation that may impact representativeness of the surveys due to enrolment bias, and affects precision of the survey estimates. To account for this limitation, survey outputs were weighted considering the eligible population size per clinic, the number of eligible individuals enrolled and the number of successful genotypes. Nevertheless, the demographic characteristics of the study population, including female‐to‐male ratio, age and geographical distribution were similar to those reported for the Nicaraguan population living with HIV [4](#jia225429-bib-0004){ref-type="ref"}, [5](#jia225429-bib-0005){ref-type="ref"}, [22](#jia225429-bib-0022){ref-type="ref"}, [23](#jia225429-bib-0023){ref-type="ref"}. A second important limitation is that differences between the actual data and some model assumptions for sample size calculations exist, including the expected PDR prevalence, the proportion of initiators with prior ARV exposure and the VL suppression rate for ADR surveys. This could also affect precision of the outcomes with wider CIs, especially for subgroup estimates.

3.2. Pretreatment HIV drug resistance survey {#jia225429-sec-0014}
--------------------------------------------

The weighted national estimate of ART initiators with prior exposure to ARVs was 12.3% (95% CI: 5.8% to 24.3%) and 85.4% (75.4% to 91.7%) for ART‐naïve. 2.3% (0.1% to 5.4%) had unknown prior exposure to ARVs. Of the 21 ART initiators reporting prior exposure to ARVs, eight reported that it was from taking ARVs for prevention of mother‐to‐child transmission of HIV (PMTCT), two from prior ART, one from pre‐exposure prophylaxis and ten were not able to identify the type of prior ARV exposure. Four ART initiators had missing data for prior ARV exposure history.

Most ART initiators with genotype results (168/171, 98.2%, 95% CI: 92.5 to 99.6) were infected with HIV‐1 subtype B, 0.6% (1/171) with subtype C and 1.2% (2/171) with recombinant forms (CRF_12_BF or CRF_02_AG).

The weighted national prevalence of PDR to any ARV was 23.4% (95% CI: 14.4% to 35.6%), and 19.3% (12.2% to 29.1%) to NNRTIs (Table [2](#jia225429-tbl-0002){ref-type="table"}). Nearly one in every five (19.3%, 12.2% to 29.1%) ART initiators had resistance to at least one of the drugs of the preferred first‐line ART regimen. As expected, NNRTI PDR was higher in ART initiators with prior ARV exposure compared with no exposure (76.2% vs. 11.0%, *p* \< 0.001). Low‐levels of PDR were observed to TDF (2.9%, 0.8% to 10.4%) and FTC (3.5%, 1.1% to 10.2%), although these estimates had low precision (Figure [1](#jia225429-fig-0001){ref-type="fig"}a). Similarly, the study was not powered to observe differences in PDR prevalence by sex. No PDR was observed to PI or integrase strand transfer inhibitors (INSTI). The most frequent PDR mutation was K103NS (15.5%) (Figure [1](#jia225429-fig-0001){ref-type="fig"}b). No INSTI, or PI resistance‐associated mutations were observed.

###### 

Prevalence of pretreatment and acquired HIV drug resistance in Nicaragua, 2016[a](#jia225429-note-0008){ref-type="fn"}

  HIV drug resistance, n/N (%, 95% CI)                     All                           Male                          Female
  -------------------------------------------------------- ----------------------------- ----------------------------- -----------------------------
  PDR                                                                                                                  
  All ART initiators                                                                                                   
  Any                                                      40/171 (23.4, 14.4 to 35.6)   22/123 (17.9, 9.9 to 30.2)    18/48 (37.5, 20.8 to 57.8)
  NNRTI                                                    33/171 (19.3, 12.2 to 29.1)   18/123 (14.6, 8.0 to 25.3)    15/48 (31.3, 19.6 to 45.8)
  NRTI                                                     18/171 (10.5, 4.9 to 21.1)    11/123 (8.9, 4.0 to 18.8)     7/48 (14.6, 5.0 to 35.5)
  ART initiators without prior ARV exposure                                                                            
  Any                                                      23/146 (15.8, 8.8 to 26.6)    16/112 (14.2, 7.4 to 25.4)    7/34 (20.6, 7.5 to 45.6)
  NNRTI                                                    16/146 (11.0, 6.0 to 19.3)    12/112 (10.7, 5.2 to 20.6)    4/34 (11.8, 5.5 to 29.8)
  NRTI                                                     10/146 (6.8, 2.7 to 16.1)     7/112 (6.2, 23.2 to 15.5)     3/34 (8.8, 1.6 to 36.8)
  ART initiators with prior ARV exposure                                                                               
  Any                                                      16/21 (76.2, 52.9 to 90.1)    6/8 (75.0, 22.9 to 96.8)      10/13 (76.9, 47.1 to 92.6)
  NNRTI                                                    16/21 (76.2, 52.9 to 90.1)    6/8 (75.0, 22.9 to 96.8)      10/13 (76.9, 47.1 to 92.6)
  NRTI                                                     7/21 (33.3, 13.9 to 60.8)     4/8 (50.0, 10.0 to 90.0)      3/13 (23.1, 5.9 to 58.8)
  ADR12                                                                                                                
  PLHIV on ART                                                                                                         
  Any                                                      22/114 (18.1, 10.6 to 29.2)   17/76 (15.6, 9.4 to 24.7)     5/38 (23.2, 7.5 to 53.0)
  NNRTI                                                    21/114 (17.5, 10.1 to 28.7)   16/76 (14.7, 9.0 to 23.2)     5/38 (23.2, 7.5 to 53.0)
  NRTI                                                     17/114 (14.9, 7.9 to 26.5)    13/76 (11.9, 6.8 to 20.0)     4/38 (21.0, 5.9 to 52.8)
  NNRTI + NRTI                                             16/114 (14.4, 7.4 to 26.1)    12/76 (11.0, 6.3 to 18.6)     4/38 (21.0, 5.9 to 52.8)
  PLHIV on ART with VL ≥1000 copies/mL                                                                                 
  Any                                                      22/27 (85.1, 66.1 to 94.4)    17/18 (94.7, 64.9 to 99.4)    5/9 (75.0, 28.3 to 95.8)
  NNRTI                                                    21/27 (82.4, 60.7 to 93.4)    16/18 (89.4, 49.5 to 98.6)    5/9 (75.0, 28.3 to 95.8)
  NRTI                                                     17/27 (70.2, 43.6 to 87.8)    13/18 (72.4, 42.3 to 90.4)    4/9 (67.9, 18.7 to 95.1)
  NNRTI + NRTI                                             16/27 (67.5, 40.0 to 86.6)    12/18 (67.1, 34.8 to 88.6)    4/9 (67.9, 18.7 to 95.1)
  PLHIV on first‐line ART with VL ≥ 1000 copies/mL                                                                     
  Any                                                      22/27 (85.1, 66.1 to 94.4)    17/18 (94.7, 64.9 to 99.4)    5/9 (75.0, 28.3 to 95.8)
  NNRTI                                                    21/27 (82.4, 60.7 to 93.4)    16/18 (89.4, 49.5 to 98.6)    5/9 (75.0, 28.3 to 95.8)
  NRTI                                                     17/27 (70.2, 43.6 to 87.8)    13/18 (72.4, 42.3 to 90.4)    4/9 (67.9, 18.7 to 95.1)
  NNRTI + NRTI                                             16/27 (67.5, 40.0 to 86.6)    12/18 (67.1, 34.8 to 88.6)    4/9 (67.9, 18.7 to 95.1)
  PLHIV on first‐line NNRTI ART with VL ≥ 1000 copies/mL                                                               
  Any                                                      21/25 (84.9, 65.4 to 94.4)    17/18 (94.7, 64.9 to 99.4)    4/7 (64.3, 18.1 to 93.6)
  NNRTI                                                    20/25 (81.3, 58.2 to 93.2)    16/18 (89.4, 49.5 to 98.6)    4/7 (64.3, 18.1 to 93.6)
  NRTI                                                     16/25 (65.3, 42.2 to 82.9)    13/18 (72.4, 42.3 to 90.4)    3/7 (50.3, 10.1 to 90.1)
  NNRTI + NRTI                                             15/25 (61.7, 38.0 to 80.9)    12/18 (67.1, 34.8 to 88.6)    3/7 (50.3, 10.1 to 90.1)
  ADR48                                                                                                                
  PLHIV on ART                                                                                                         
  Any                                                      87/353 (22.2, 18.3 to 26.6)   58/219 (26.2, 20.9 to 32.3)   29/134 (16.9, 11.2 to 24.8)
  NNRTI                                                    82/353 (20.8, 17.2 to 24.9)   55/219 (25.1, 19.9 to 31.1)   27/134 (15.2, 9.9 to 22.5)
  NRTI                                                     68/353 (17.5, 14.2 to 21.2)   48/219 (21.4, 16.5 to 27.2)   20/134 (12.3, 7.6 to 19.3)
  PI                                                       6/353 (1.4, 0.8 to 2.3)       5/219 (1.9, 1 to 3.6)         1/134 (0.6, 0.1 to 4.0)
  NNRTI + NRTI                                             63/353 (16.1, 13.1 to 19.6)   45/219 (20.3, 15.5 to 26.1)   18/134 (10.5, 6.4 to 16.9)
  PLHIV on ART with VL ≥1000 copies/mL                                                                                 
  Any                                                      87/110 (75.5, 63.5 to 84.5)   58/71 (82.9, 72 to 90.2)      29/39 (63.8, 39.3 to 82.8)
  NNRTI                                                    82/110 (70.7, 58.7 to 80.3)   55/71 (79.4, 68 to 87.4)      27/39 (57.2, 34.5 to 77.2)
  NRTI                                                     68/110 (59.4, 48.1 to 69.8)   48/71 (67.7, 53.9 to 79.0)    20/39 (46.4, 27.5 to 66.4)
  PI                                                       6/110 (4.6, 2.2 to 9.5)       5/71 (6.1, 2.7 to 13.4)       1/39 (2.2, 0.2 to 19.8)
  NNRTI + NRTI                                             63/110 (54.6, 43.3 to 65.4)   45/71 (64.2, 50.3 to 76.0)    18/39 (39.7, 22.6 to 59.9)
  PLHIV on first‐line ART with VL ≥1000 copies/mL                                                                      
  Any                                                      75/93 (77.3, 63.3 to 87.0)    49/58 (85.6, 73.2 to 92.8)    26/35 (64.2, 37 to 84.6)
  NRTI                                                     70/93 (71.6, 57.7 to 82.3)    46/58 (81.4, 68.4 to 89.8)    24/35 (56.2, 31.3 to 78.4)
  NNRTI                                                    58/93 (59.7, 46.8 to 71.4)    41/58 (70.2, 54.5 to 82.3)    17/35 (43.2, 23.5 to 65.4)
  PI                                                       2/93 (1.8, 0.5 to 6.0)        2/58 (2.9, 0.7 to 10.7)       0/35
  NNRTI + NRTI                                             53/93 (54, 41.3 to 66.2)      38/58 (66.0, 50.4 to 78.7)    15/35 (35.2, 18 to 57.4)
  PLHIV on first‐line NNRTI ART with VL ≥1000 copies/mL                                                                
  Any                                                      69/80 (82.4, 66.4 to 91.8)    46/51 (91.9, 80.6 to 96.9)    23/29 (68.1, 36.7 to 88.7)
  NNRTI                                                    66/80 (78.1, 62.3 to 88.4)    45/51 (90.4, 78 to 96.2)      21/29 (59.4, 31.3 to 82.5)
  NRTI                                                     53/80 (63.8, 49.5 to 76.0)    38/51 (74.5, 56.7 to 86.7)    15/29 (47.6, 25.3 to 71.0)
  PI                                                       2/80 (1.8, 0.4 to 7.3)        2/51 (3.1, 0.7 to 12.1)       0/29
  NNRTI + NRTI                                             50/80 (59.4, 45.3 to 72.2)    37/51 (73, 54.9 to 85.7)      13/29 (39.0, 19.3 to 63.0)

ART, antiretroviral therapy; ARV, antiretroviral; ATV/r, atazanavir/ritonavir; CI, confidence interval; DRV/r, darunavir/ritonavir; EFV, efavirenz; FTC, emtricitabine; HIVDR, HIV drug resistance; LPV/r, lopinavir/ritonavir; NNRTI, non‐nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; TDF, tenofovir.

Study design‐weighted proportions and 95% confidence intervals. Resistance was defined as a penalty score ≥15 using the Stanford HIVdb tool (v8.2). Any HIVDR was defined as resistance to one or more of the following drugs: NVP, EFV, any NRTI, DRV/r, LPV/r, or ATV/r; HIVDR to NRTI was defined as resistance to any NRTI; HIVDR to NNRTI was defined as resistance to NVP and EFV. Preferred first‐line ART regimen: TDF + FTC+EFV.

John Wiley & Sons, Ltd

![**Pretreatment and acquired HIV drug resistance prevalence and patterns in Nicaragua, 2016. Resistance was defined as a penalty score ≥15 using the Stanford HIVdb tool (v8.2).**\
**(a)** PDR prevalence by drug, **(b)** Frequency of PDR mutations, **(c)** ADR12/ADR48 prevalence by drug and **(d)** Frequency of ADR12/ADR48 mutations. Study design‐weighted proportions and 95% confidence intervals are shown. Only major HIVDR mutations are shown. No INSTI or PI mutations were observed for the PDR and ADR12 surveys. No INSTI mutations were observed for the ADR48 survey. 3TC/FTC, lamivudine/emtricitabine; ABC, abacavir; ADR12, acquired drug resistance at 12 (±3) months on ART; ADR48, acquired drug resistance at ≥48 months on ART; ATV/r, atazanavir/ritonavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; DRV/r, darunavir/ritonavir; EFV, efavirenz; ETR, etravirine; FPV/r, fosamprenavir/ritonavir; IDV/r, indinavir/ritonavir; INSTI, integrase strand transfer inhibitor; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NNRTI, non‐nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PDR, pretreatment drug resistance; PI, protease inhibitor; RPV, rilpivirine; SQV/r, saquinavir/ritonavir; TDF, tenofovir; TPV/r, tipranavir.](JIA2-22-e25429-g001){#jia225429-fig-0001}

Our study suggests high NNRTI PDR level in Nicaragua, crossing the 10% threshold defined by the WHO for urgent programmatic action [24](#jia225429-bib-0024){ref-type="ref"}. As previously observed in other countries [25](#jia225429-bib-0025){ref-type="ref"}, NNRTI PDR was higher in ART initiators with prior ARV exposure compared with persons with no exposure, indicating a risk group amenable to immediate intervention. Although the goal sample size for the survey was not achieved, a critical limitation that may affect representativeness and produce estimates with wider CIs, we accounted for this limitation by applying a weighting process to estimate survey outcomes. Using this approach, the lower end of the 95% CI for NNRTI PDR was 12.2%, which provides strong evidence that NNRTI PDR has crossed the 10% threshold in Nicaragua.

Given the observed results, the National HIV Program might consider initiating ART with non‐NNRTI‐based regimens as the preferred option, prioritizing ART initiators with prior exposure to ARVs [24](#jia225429-bib-0024){ref-type="ref"}, [26](#jia225429-bib-0026){ref-type="ref"}. The observed low‐level rates of PDR to TDF and FTC suggests that an ART backbone based on these drugs could be effective. Considering this scenario, the WHO‐recommended fixed‐dose combination of TDF, 3TC and dolutegravir may be a good option for the preferred first‐line ART regimen in Nicaragua [27](#jia225429-bib-0027){ref-type="ref"}.

3.3. Acquired HIV drug resistance surveys {#jia225429-sec-0015}
-----------------------------------------

Several obstacles were met to reach the goal sample size for the ADR12 survey. The national retention rate at 12 months after ART initiation for adults ≥15 years old in Nicaragua was low (72%) for the survey period [21](#jia225429-bib-0021){ref-type="ref"}, representing a considerable challenge for survey enrolment. We attempted to account for this limitation by weighting the survey outcomes by eligible population size per clinic, number of eligible individuals enrolled and proportion of successful sequences, as well as adjusting for the national ART retention rate. Considering this limitation, the weighted national estimate prevalence of VL suppression was 77.8% (95% CI: 67.1% to 85.8%) among PLHIV on ART for 12 (±3) and 70.3% (66.7% to 73.8%) among those on ART for ≥48 months (Table [3](#jia225429-tbl-0003){ref-type="table"}). The retention‐adjusted VL suppression estimate was 56.0% (48.1% to 63.9%) among PLHIV on ART for 12 (±3) months.

###### 

Prevalence estimates of viral load suppression among PLHIV on ART for 12 (±3) or ≥48 months, Nicaragua, 2016[a](#jia225429-note-0010){ref-type="fn"}

                                        ADR12    ADR48                           
  ------------------------------------- -------- --------------------- --------- ---------------------
  PLHIV on ART                          86/114   77.8 (67.1 to 85.8)   240/353   70.3 (66.7 to 73.8)
  Male                                  58/76    83.5 (73.8 to 90.2)   148/219   68.7 (62.2 to 74.5)
  Female                                28/38    66.4 (42.7 to 84.0)   92/134    72.5 (65.2 to 78.8)
  ≤25 years                             21/27    77.2 (45.6 to 93.2)   11/27     51.5 (23.0 to 79.1)
  \>25 years                            65/87    78.2 (70.9 to 84.0)   229/326   72.2 (68.1 to 75.9)
  PLHIV on first‐line ART               82/110   77.3 (66.4 to 85.5)   208/303   70.9 (66.8 to 74.6)
  Male                                  54/72    83.0 (79.0 to 86.3)   126/184   69.2 (63.5 to 74.3)
  Female                                28/38    66.4 (45.0 to 82.7)   82/119    73.2 (66.9 to 78.7)
  ≤25 years                             21/27    77.2 (44.7 to 93.4)   8/21      55.9 (37.7 to 72.6)
  \>25 years                            61/83    77.4 (70.9 to 82.8)   200/282   72.3 (68.0 to 76.2)
  PLHIV on first‐line NNRTI‐based ART   78/104   80.7 (76.1 to 84.7)   182/264   70.3 (65.7 to 74.4)
  Male                                  54/72    83.0 (79.0 to 86.3)   112/163   68.9 (62.8 to 74.4)
  Female                                24/32    74.7 (60.5 to 85.1)   70/101    72.1 (64.7 to 78.4)
  ≤25 years                             21/26    88.9 (81.2 to 93.7)   5/16      33.3 (14.5 to 59.5)
  \>25 years                            57/78    76.8 (69.7 to 82.6)   177/248   72.9 (68.2 to 77.1)

ADR12, acquired drug resistance at 12 (±3) months on ART; ADR48, acquired drug resistance at ≥48 months on ART; ART, antiretroviral therapy; CI, confidence interval; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PLHIV, people living with HIV.

Study design‐weighted proportions and 95% confidence intervals. VL suppression was defined as \<1000 copies/mL.

John Wiley & Sons, Ltd

The prevalence of VL suppression in Nicaragua was lower than that observed in a systematic review of ADR studies in adults from LMICs during the period 2014 to 2017 [28](#jia225429-bib-0028){ref-type="ref"}. High PDR prevalence may partially explain suboptimal VL suppression levels at 12 (±3) months on ART. However, the even lower rate of VL suppression observed among persons on ART for ≥48 months suggests programmatic weaknesses that need to be addressed. No differences on VL suppression associated to sex or age were evident, although the low precision of estimates may reduce study power to detect differences. Analysis of WHO early warning indicators of HIVDR and the identification of specific ART sites with poor performance could be useful to ascertain intervention opportunities [29](#jia225429-bib-0029){ref-type="ref"}, such as: adherence strengthening programmes, loss‐to‐follow‐up prevention, improvement of VL testing coverage and prevention of drug stock‐outs [8](#jia225429-bib-0008){ref-type="ref"}.

The prevalence of HIVDR among PLHIV on ART who had not achieved VL suppression, was 85.1% (95% CI: 66.1% to 94.4%) in ADR12 and 75.5% (63.5% to 84.5%) in ADR48 (Table [2](#jia225429-tbl-0002){ref-type="table"}). PI resistance was only observed in the ADR48 survey, 4.6% (2.2% to 9.5%) among those with unsuppressed VL. No INSTI resistance was observed in any of the surveys. HIVDR to EFV or NVP was \>70% among PLHIV with unsuppressed VL in both ADR surveys (Figure [1](#jia225429-fig-0001){ref-type="fig"}c). The proportion of HIVDR to at least one NRTI of the preferred second‐line regimen, among PLHIV on first‐line ART with unsuppressed VL, was 64.9% in ADR12 and 54.5% in ADR48. The most frequent mutations were K103NS (ADR12: 74.4%; ADR48: 61.5%) and M184IV (ADR12: 64.9%; ADR48: 54.5%) (Figure [1](#jia225429-fig-0001){ref-type="fig"}d).

The high levels of HIVDR to NNRTI and NRTI among individuals on ART with unsuppressed VL are consistent with previously observed data in LMICs [28](#jia225429-bib-0028){ref-type="ref"}. The high proportion of HIVDR to NRTI suggests prolonged periods of exposure to suboptimal ART, warranting actions for rapid identification and switch of PLHIV failing first‐line ART, in order to preserve the NRTI backbone. Overall, ADR mutation patterns were similar to those observed in other Central American countries, with predominance of K103NS and M184V [30](#jia225429-bib-0030){ref-type="ref"}, [31](#jia225429-bib-0031){ref-type="ref"}. Our results suggest that currently recommended second‐line PI‐based regimens in Nicaragua remain an effective option for most individuals failing first‐line [3](#jia225429-bib-0003){ref-type="ref"}.

Approximately 20% of PLHIV receiving first‐line ART with VL ≥1000 copies/mL in Nicaragua did not have HIVDR. As previously shown [32](#jia225429-bib-0032){ref-type="ref"}, enhanced and tailored adherence support programmes, associated with a strengthened VL testing system, could be useful for such individuals to achieve viral suppression without the need to switch to a second‐line ART regimen.

4. Conclusions {#jia225429-sec-0016}
==============

Despite implementation challenges possibly affecting national representativeness and yielding low‐precision HIVDR estimates, important aspects of HIVDR were observed, including a high NNRTI PDR prevalence, above the 10% threshold suggested by the WHO for urgent programmatic action. This statistic combined with low viral suppression rates and high ADR levels warrant programmatic action. Negotiations to introduce non‐NNRTI‐based first‐line ART regimens and the strengthening of VL monitoring and follow‐up activities would benefit the national HIV programme.

We acknowledge that the surveys were implemented in 2016, which implies that HIVDR estimates may have changed with time. However, looking at increasing global and regional NNRTI PDR trends [1](#jia225429-bib-0001){ref-type="ref"}, [25](#jia225429-bib-0025){ref-type="ref"}, our data suggest that HIVDR could become an even more relevant issue in Nicaragua.
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